Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.2 (
alanine aminotransferase
)
26,722
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
An intravenous injection of Concanavalin A (Con A) elevated the serum level of
alanine aminotransferase
(
ALT
) activity, a marker for liver damage, and an oral administration of
PDE7A
inhibitor SUN11817 suppressed the increase of
ALT
activity in a dose-dependent manner. Histological analysis revealed that Con A injection caused extensive liver damage, and that the SUN11817 treatment improved the degenerative change in the liver. In addition, SUN11817 inhibited not only the production of IL-4 and TNF-alpha in the Con A-induced hepatitis model but also that in vitro by murine splenocytes stimulated with alpha-galactosylceramide, an activator specific for NKT cells. The Con A injection to mice also induced expression of Fas ligand (FasL) on NKT cells, which was significantly prevented by SUN11817. As NKT cells are known to contribute to the pathogenesis in Con A-induced hepatitis by producing cytokines such as IL-4 and TNF-alpha and inducing FasL-mediated hepatocyte injury, it is thought that
PDE7A
inhibitor SUN11817 improves liver injury in the Con A model by blocking cytokine production and FasL expression in NKT cells.
PDE7A
might be a novel pharmaceutical target for hepatitis.
...
PMID:Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice. 1967 49
